TCON - トラコン・ファ―マシュ―ティカルズ （TRACON Pharmaceuticals Inc.） トラコン・ファ―マシュ―ティカルズTCONのチャート
TCONの企業情報
| symbol | TCON |
|---|---|
| 会社名 | TRACON Pharmaceuticals Inc （トラコン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 TRACON Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate TRC105 is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102 a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. トラコン・ファ―マシュ―ティカルズは、米国の臨床バイオ製薬会社。がん、加齢性黄斑変性症(AMD)および線維性疾患の治療のために、製品の開発、実用化に注力する。同社の製品には、血管内皮増殖因子(VEGF)経路の阻害剤と組み合わせ、複数の固形腫瘍タイプの治療のために開発された抗エンドグリン抗体TRC105がある。 tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w |
| 本社所在地 | 4350 La Jolla Village Drive Suite 800 San Diego CA 92122 USA |
| 代表者氏名 | Charles P. Theuer チャールズP.テュア |
| 代表者役職名 | President Chief Executive Officer Principal Financial Officer Principal Accounting Officer Director |
| 電話番号 | +1 858-550-0780 |
| 設立年月日 | 38261 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 25人 |
| url | www.traconpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tcon |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -22.85800 |
| 終値（lastsale） | 1.9 |
| 時価総額（marketcap） | 56697603.6 |
| 時価総額 | 時価総額（百万ドル） 54.60874 |
| 売上高 | 売上高（百万ドル） 10.49800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7.49974 |
| 当期純利益 | 当期純利益（百万ドル） -23.50800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 TRACON Pharmaceuticals Inc revenues increased from $1.3M to $3M. Net loss increased 32% to $18.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.84 to -$0.79. |
TCONのテクニカル分析
TCONのニュース
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Sees Significant Drop in Short Interest 2023/05/26 07:32:42 The AM Reporter
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON – Get Rating) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 161,000 shares, a decline of 38.7% from the April 30th total of 262,500 shares. Based on an average daily trading volume, of 181,900 shares, […]
Baird maintains TRACON Pharma at ''outperform'' with a price target of $7.00 2023/05/11 11:57:34 Investing.com
https://www.investing.com/news/pro/tracon-pharmaceuticals-inc-receives-investment-bank-analyst-rating-update-3079941
TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript 2023/05/11 02:18:09 Seeking Alpha
TRACON Pharmaceuticals, Inc. (NASDAQ:NASDAQ:TCON) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ETCompany ParticipantsCharles Theuer - CEO, President & DirectorScott Brown -…
Recap: TRACON Pharma Q1 Earnings 2023/05/10 21:15:41 Benzinga
TRACON Pharma (NASDAQ: TCON ) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:02 PM. Here''s what investors need to know about the announcement. Earnings TRACON Pharma missed estimated earnings by 38.46%, reporting an … Full story available on Benzinga.com
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update 2023/05/10 20:02:00 GlobeNewswire
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
TRACON Pharmaceuticals And 2 Other Stocks Under $3 Insiders Are Aggressively Buying 2023/05/01 13:37:07 Benzinga
The Dow Jones closed higher by more than 250 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. NN The Trade: NN, Inc. (NASDAQ: NNBR ) 10% owner Hjalmar Eric Soderlund acquired a total 95,053 shares an average price of $1.04. To acquire these shares, it cost around $98.76 thousand. What’s Happening: NN opened a state-of-the-art 50,000+ square foot facility in São Paulo, Brazil. What NN … Full story available on Benzinga.com
I─Mab announces positive outcome in arbitration relating to agreements with Tracon Pharma 2023/04/26 12:14:46 EIN News Pharmaceuticals
… of its arbitration with Tracon Pharmaceuticals (Tracon) relating to (1) the …
Tracon Pharmaceuticals Plunges after Unfavorable Arbitration Ruling 2023/04/25 15:48:04 TipRanks
I-Mab (NASDAQ:IMAB) recently went through an arbitration tribunal with Tracon Pharmaceuticals (NASDAQ:TCON) over a couple of collaboration agreemen…
Baudax, Petros top healthcare gainers; Tracon, Maia among losers 2023/04/25 14:06:07 Seeking Alpha
Baudax Bio (BXRX) +48%. Petros Pharmaceuticals (PTPI) +48%. Tracon Pharmaceuticals (TCON) -43%. Maia Biotechnology (MAIA) -21%.
Nikola (NKLA) Stock Pops on Canadian Expansion News 2023/04/25 14:02:22 InvestorPlace
Nikola (NASDAQ: NKLA ) stock is getting a boost on Tuesday following news that the EV company is expanding its business to Canada . According to a press release from the EV company, it’s expanded into Alberta, Canada with the sale of a Nikola Tre battery-electric vehicle (BEV) and a Nikola Tre hydrogen fuel cell electric vehicle (FCEV). These were sold to the Alberta Motor Transport Association (AMTA). AMTA intends to introduce these vehicles in its Hydrogen Commercial Vehicle Demonstrations Project. The organization has also secured the refueling support needed for them from Nikola. Doug Paisley, Board chair at AMTA, said the following about the purchase. “We are excited to put these Nikola trucks to work in Alberta and begin collecting performance data, raising awareness to this advanced technology, promoting early adoption, and creating industry confidence in such an innovative technology.” What This Means For NKLA Stock Investors are excited about what this news means for NKLA stock.
TRACON Pharmaceuticals Inc. (NASDAQ: TCON) Stock Forecast: Bullish Signals Pointing To $14.00 In 2023 2023/01/16 18:00:00 Marketing Sentinel
In the last trading session, 81865.0 shares of the TRACON Pharmaceuticals Inc. (NASDAQ:TCON) were traded, and its beta was 1.35. Most recently the company’s share price was $1.78, and it changed around $0.02 or 1.31% from the last close, which brings the market valuation of the company to $39.10M. TCON currently trades at a discount … TRACON Pharmaceuticals Inc. (NASDAQ: TCON) Stock Forecast: Bullish Signals Pointing To $14.00 In 2023 Read More »
Investing in TRACON Pharmaceuticals Inc. (TCON) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/12/28 13:32:00 US Post News
As of Tuesday, TRACON Pharmaceuticals Inc.’s (NASDAQ:TCON) stock closed at $1.44, up from $1.30 the previous day. While TRACON Pharmaceuticals Inc. has overperformed by 10.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TCON fell by -50.52%, with highs and lows ranging from $3.30 to $1.10, […]
TRACON Pharmaceuticals announced $30M attributed to award decision expected in Q1 2023 2022/12/27 15:49:17 Seeking Alpha
TRACON Pharmaceuticals (TCON) announced entry into an up to $30M non-recourse financing agreement.$3.5M will be funded before December 31, 2022